Table 2.
Treatment outcomes of metastatic UM on combination ipilimumab and nivolumab
| Total cycles of ipilimumab +nivolumab | |
| 1 | 14 (16%) |
| 2 | 20 (22%) |
| 3 | 18 (20%) |
| 4 | 37 (42%) |
| Median | 3 |
| Reason for ipilimumab +nivolumab discontinuation | |
| Progression | 18 (35%) |
| Toxicity | 29 (57%) |
| NA | 4 (8%) |
| Maintenance therapy | |
| Ipilimumab | 1 (1%) |
| Nivolumab | 26 (29%) |
| Pembrolizumab | 2 (2%) |
| No maintenance therapy | 46 (52%) |
| NA | 14 (16%) |
| Reason maintenance therapy discontinuation | |
| Progression | 16 (55%) |
| Toxicity | 5 (17%) |
| Still on nivolumab | 2 (7%) |
| Unknown status | 6 (21%) |
| Number of doses of nivolumab monotherapy | |
| Median | 7 |
| Range | 1–29 |
| NA | 4 |
NA, not applicable; UM, uveal melanoma.